Gene Therapy Market to be Worth Over USD 10 Billion by 2025, Predicts Roots Analysis
The report contains detailed analysis of the Gene Therapy market and forecasts the demand of the market in the coming decade.
Mohali, India, June 12, 2015 --(PR.com)-- Roots Analysis has announced the addition of “Gene Therapy Market, 2015-2025” report to their offering. The market currently has only five approved therapies; of these, four are commercialised in geographies other than the US and EU. Roots Analysis’ latest research provides in depth insights not only on the approved therapies (Gendicine, Rexin-G, Oncorine, Neovasculgen and Glybera) but also on several other therapies in late stage of development.
Ishita Nanda, the principal analyst, said, “Due to the stringent FDA and EMA regulations, gene therapy has so far made its entry only in the Asian markets; it is yet to be made commercially available in the developed markets. However, with a robust pipeline of close to 500 molecules, the future looks highly promising. Active participation of the venture capital firms is significantly backing up the massive research being carried out for upcoming gene therapies.”
Nanda further stated, “The current approach is likely to result in several commercial success stories in the foreseeable future. Our study covers various aspects, such as key players, marketed gene therapy products, products in clinical / pre-clinical research, likely future developments and upcoming opportunities for a variety of stakeholders. We have identified the development and sales potential based on target consumer segments, likely adoption rate and expected pricing.”
Some of the key insights captured in the 279 page detailed report include:
20% of therapies are in late stage of clinical development; Oncology based gene therapies are the most popular, accounting for 42% of the total pipeline.
Interest from venture capital firms is growing; during January 2013 to April 2014, a total USD 600 million was raised by the US companies alone.
The market, estimated to grow at a CAGR of 48.9% over the coming decade, is likely to be worth USD 11 billion by 2025; specific therapies such as Prostavac, ProstAtak and TroVax are likely to achieve blockbuster status.
Who will benefit from this report?
This research is targeted towards pharma companies and research groups working in the field of gene therapy. In particular, you will benefit if you are an:
Investor
Contract manufacturer
R&D Manager
Business Intelligence / Scientific Analyst
Licensing / Portfolio Manager
Strategy Manager
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Ishita Nanda, the principal analyst, said, “Due to the stringent FDA and EMA regulations, gene therapy has so far made its entry only in the Asian markets; it is yet to be made commercially available in the developed markets. However, with a robust pipeline of close to 500 molecules, the future looks highly promising. Active participation of the venture capital firms is significantly backing up the massive research being carried out for upcoming gene therapies.”
Nanda further stated, “The current approach is likely to result in several commercial success stories in the foreseeable future. Our study covers various aspects, such as key players, marketed gene therapy products, products in clinical / pre-clinical research, likely future developments and upcoming opportunities for a variety of stakeholders. We have identified the development and sales potential based on target consumer segments, likely adoption rate and expected pricing.”
Some of the key insights captured in the 279 page detailed report include:
20% of therapies are in late stage of clinical development; Oncology based gene therapies are the most popular, accounting for 42% of the total pipeline.
Interest from venture capital firms is growing; during January 2013 to April 2014, a total USD 600 million was raised by the US companies alone.
The market, estimated to grow at a CAGR of 48.9% over the coming decade, is likely to be worth USD 11 billion by 2025; specific therapies such as Prostavac, ProstAtak and TroVax are likely to achieve blockbuster status.
Who will benefit from this report?
This research is targeted towards pharma companies and research groups working in the field of gene therapy. In particular, you will benefit if you are an:
Investor
Contract manufacturer
R&D Manager
Business Intelligence / Scientific Analyst
Licensing / Portfolio Manager
Strategy Manager
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact
Roots Analysis
Ashish Ganguli
172-4644848
www.rootsanalysis.com
Ashish Ganguli
172-4644848
www.rootsanalysis.com
Contact
Categories